DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Fosrenol (Lanthanum Carbonate Hydrate) - Published Studies

 
 



Fosrenol Related Published Studies

Well-designed clinical trials related to Fosrenol (Lanthanum Carbonate)

Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study. [2011.05]

The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. [2011.05]

Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. [2011.03]

Efficacy of chewed vs. crushed lanthanum on phosphorus binding in healthy volunteers. [2010.05]

Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. [2009.12]

Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. [2009.10]

Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. [2009.01]

Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. [2008.11]

Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. [2007.11]

Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. [2007.02]

Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. [2006.08]

Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. [2006.07]

Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. [2006.03]

Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. [2006]

The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. [2005.12]

Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. [2005.06]

Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. [2005.04]

Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. [2005]

Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. [2004.09]

Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. [2003.07]

A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. [2003.06]

Well-designed clinical trials possibly related to Fosrenol (Lanthanum Carbonate)

Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. [2011.02]

Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. [2009.10]

Other research related to Fosrenol (Lanthanum Carbonate)

Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study. [2012]

Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective. [2012]

Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study. [2011.09.30]

Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis. [2011.09]

Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. [2011.06.24]

Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. [2011.06]

[Efficacy and safety of lanthanum carbonate in chronic kidney disease patients with hyperphosphataemia]. [2011.06]

Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure. [2011.06]

Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders. [2011.05]

Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia. [2011.04]

Measurement of serum lanthanum in patients treated with lanthanum carbonate by inductively coupled plasma-mass spectrometry. [2011.03]

Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients. [2011.02]

Pharmacology of the phosphate binder, lanthanum carbonate. [2011]

Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective. [2011]

Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis. [2011]

Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. [2011]

Phosphate-binding efficacy of crushed vs. chewed lanthanum carbonate in hemodialysis patients. [2010.12.07]

Three-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patients. [2010.12]

A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice. [2010.11]

Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders. [2010.07]

[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease]. [2010.07]

One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis. [2010.02]

Overestimation of lumbar spine calcium with dual energy X-ray absorptiometry scanning due to the prescription of lanthanum carbonate in patients with chronic kidney disease. [2010]

Tissue accumulation of lanthanum as compared to aluminum in rats with chronic renal failure--possible harmful effects after long-term exposure. [2010]

Efficacy of chewed vs. crushed lanthanum on phosphorus binding in healthy volunteers. [2010]

Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease. [2009.11.12]

Lanthanum deposition in a dialysis patient. [2009.10]

A confusional state associated with use of lanthanum carbonate in a dialysis patient: a case report. [2009.10]

Dietary administration in rodent studies distorts the tissue deposition profile of lanthanum carbonate; brain deposition is a contamination artefact? [2009.08.10]

Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease. [2009.08]

Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats. [2009.06]

Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. [2009.03]

[Is lanthanum carbonate a safe drug?] [2009.02]

[Management of phosphate in chronic kidney disease--Clinical trials of lanthanum carbonate] [2009.02]

[Pharmacodynamic and pharmacokinetic profile of lanthanum carbonate] [2009.02]

Lanthanum and phosphate: science, policy, and survival. [2009.02]

Hepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failure. [2009.02]

Therapeutic use of the phosphate binder lanthanum carbonate. [2009.01]

Calciphylaxis responsive to lanthanum carbonate (FOSRENOL) therapy. [2008.11]

Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. [2008.11]

Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. [2008.10]

Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. [2008.09]

Higher Strength Lanthanum Carbonate Provides Serum Phosphorus Control With a Low Tablet Burden and Is Preferred by Patients and Physicians: A Multicenter Study. [2008.06.25]

[Radiographic characteristics of lanthanum carbonate absorption] [2008.04]

Lanthanum Carbonate Effectively Controls Serum Phosphate Without Affecting Serum Calcium Levels in Patients Undergoing Hemodialysis. [2008.02]

[Lanthanum carbonate in clinical practice] [2008]

[Introduction to lanthanum carbonate: pharmacology, safety and tolerability] [2008]

Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. [2008]

Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. [2008]

A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate. [2008]

A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. [2007.12]

Effects of Lanthanum Carbonate on the Absorption and Oral Bioavailability of Ciprofloxacin. [2007.10.03]

Lanthanum carbonate as a first-line phosphate binder: the "cons". [2007.07]

Lanthanum carbonate--a first line phosphate binder? [2007.07]

Systemic lanthanum is excreted in the bile of rats. [2007.06.15]

Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate. [2007.04]

Lanthanum carbonate: time to abandon prejudices? [2007.02]

Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats. [2007.02]

The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease. [2007.01]

Clinical consequences and novel therapy of hyperphosphatemia: Lanthanum carbonate for dialysis patients. [2007.01]

Clinical consequences and novel therapy of hyperphosphatemia: Lanthanum carbonate for dialysis patients. [2007.01]

Lanthanum carbonate. [2006.12]

Lanthanum: a safe phosphate binder. [2006.05]

Lanthanum carbonate. [2006.02]

Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients. [2005.09]

A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. [2005.05]

Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. [2005.05]

Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients. [2005.02]

Assessment of effects of lanthanum carbonate with and without phosphate supplementation on bone mineralization in uremic rats. [2005.02]

Utilization of bone histomorphometry in renal osteodystrophy: demonstration of a new approach using data from a prospective study of lanthanum carbonate. [2005.02]

Blast from the past: the aluminum's ghost on the lanthanum salts. [2005]

Lanthanum carbonate: a new phosphate binder. [2004.07]

Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. [2004.07]

Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. [2004]

Lanthanum carbonate (Shire). [2003.07]

Other possibly related research studies

Effects of efficient phosphate binding on bone in chronic renal failure rats. [2005]

The clinical management of hyperphosphatemia. [2005.05]

Improving phosphate-binder therapy as a way forward. [2004.03]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014